147 related articles for article (PubMed ID: 30911762)
21. Dress syndrome secondary to different combinations of targeted therapy (iBRAF + iMEK).
Robert M; Jantzem H; Etienne M; Misery L
Eur J Dermatol; 2020 Jun; 30(3):303-304. PubMed ID: 32666930
[No Abstract] [Full Text] [Related]
22. Network meta-analysis of therapies for previously untreated advanced BRAF-mutated melanoma.
Zoratti MJ; Devji T; Levine O; Thabane L; Xie F
Cancer Treat Rev; 2019 Mar; 74():43-48. PubMed ID: 30798169
[TBL] [Abstract][Full Text] [Related]
23. Targeted agents or immuno-oncology therapies as first-line therapy for BRAF-mutated metastatic melanoma: a real-world study.
Luke JJ; Ghate SR; Kish J; Lee CH; McAllister L; Mehta S; Ndife B; Feinberg BA
Future Oncol; 2019 Sep; 15(25):2933-2942. PubMed ID: 30799646
[No Abstract] [Full Text] [Related]
24. A monocentric phase I study of vemurafenib plus cobimetinib plus PEG-interferon (VEMUPLINT) in advanced melanoma patients harboring the V600BRAF mutation.
Simeone E; Scognamiglio G; Capone M; Giannarelli D; Grimaldi AM; Mallardo D; Madonna G; Curvietto M; Esposito A; Sandomenico F; Sabbatino F; Bayless NL; Warren S; Ong S; Botti G; Flaherty KT; Ferrone S; Ascierto PA
J Transl Med; 2021 Jan; 19(1):17. PubMed ID: 33407577
[TBL] [Abstract][Full Text] [Related]
25. Systemic inflammatory reaction syndrome during combined kinase inhibitor therapy following anti-PD-1 therapy for melanoma.
Urosevic-Maiwald M; Mangana J; Dummer R
Ann Oncol; 2017 Jul; 28(7):1673-1675. PubMed ID: 28459947
[No Abstract] [Full Text] [Related]
26. Vemurafenib and cobimetinib in BRAF-mutated melanoma.
Rahman A
Lancet Oncol; 2014 Nov; 15(12):e535. PubMed ID: 25602110
[No Abstract] [Full Text] [Related]
27. Erythema multiforme-like rash upon anti-melanoma therapy with BRAF and MEK inhibitors.
Grän F; Goebeler M; Gesierich A
Eur J Dermatol; 2019 Feb; 29(1):107-108. PubMed ID: 30998207
[No Abstract] [Full Text] [Related]
28. Stevens-Johnson Syndrome and Severe Anaemia: A Case of Toxicity Induced by Vemurafenib plus Cobimetinib following Pembrolizumab for Metastatic Melanoma.
Batinac T; Hlača N; Simetić L; Valković F; Peternel S; Prpić-Massari L
Acta Derm Venereol; 2022 Feb; 102():adv00650. PubMed ID: 35146529
[No Abstract] [Full Text] [Related]
29. Characterization and Outcomes of Disease Progression in 52 Patients Treated with BRAF-V600 + MEK Inhibitors for Advanced Melanoma.
Lucas P; Boulinguez S; Sibaud V; Mourey L; Lamant L; Paul C; Meyer N
Dermatology; 2018; 234(3-4):92-98. PubMed ID: 30110681
[TBL] [Abstract][Full Text] [Related]
30. 5-Year Outcomes with Cobimetinib plus Vemurafenib in BRAFV600 Mutation-Positive Advanced Melanoma: Extended Follow-up of the coBRIM Study.
Ascierto PA; Dréno B; Larkin J; Ribas A; Liszkay G; Maio M; Mandalà M; Demidov L; Stroyakovskiy D; Thomas L; de la Cruz-Merino L; Atkinson V; Dutriaux C; Garbe C; Hsu J; Jones S; Li H; McKenna E; Voulgari A; McArthur GA
Clin Cancer Res; 2021 Oct; 27(19):5225-5235. PubMed ID: 34158360
[TBL] [Abstract][Full Text] [Related]
31. Adjunction of a MEK inhibitor to Vemurafenib in the treatment of metastatic melanoma results in a 60% reduction of acute kidney injury.
Teuma C; Pelletier S; Amini-Adl M; Perier-Muzet M; Maucort-Boulch D; Thomas L; Laville M; Fouque D; Dalle S
Cancer Chemother Pharmacol; 2017 May; 79(5):1043-1049. PubMed ID: 28396940
[TBL] [Abstract][Full Text] [Related]
32. Impact of initial treatment and prognostic factors on postprogression survival in BRAF-mutated metastatic melanoma treated with dacarbazine or vemurafenib ± cobimetinib: a pooled analysis of four clinical trials.
Ascierto PA; Ribas A; Larkin J; McArthur GA; Lewis KD; Hauschild A; Flaherty KT; McKenna E; Zhu Q; Mun Y; Dréno B
J Transl Med; 2020 Aug; 18(1):294. PubMed ID: 32746839
[TBL] [Abstract][Full Text] [Related]
33. Biomarkers of treatment benefit with atezolizumab plus vemurafenib plus cobimetinib in BRAF
Robert C; Lewis KD; Gutzmer R; Stroyakovskiy D; Gogas H; Protsenko S; Pereira RP; Eigentler T; Rutkowski P; Demidov L; Caro I; Forbes H; Shah K; Yan Y; Li H; McArthur GA; Ascierto PA
Ann Oncol; 2022 May; 33(5):544-555. PubMed ID: 35131452
[TBL] [Abstract][Full Text] [Related]
34. [Cobimetinib/vemurafenib-associated bilateral serous retinopathy: a case report].
Kastl G
Ophthalmologe; 2019 Aug; 116(8):785-788. PubMed ID: 30357465
[TBL] [Abstract][Full Text] [Related]
35. Indirect treatment comparison of dabrafenib plus trametinib versus vemurafenib plus cobimetinib in previously untreated metastatic melanoma patients.
Daud A; Gill J; Kamra S; Chen L; Ahuja A
J Hematol Oncol; 2017 Jan; 10(1):3. PubMed ID: 28052762
[TBL] [Abstract][Full Text] [Related]
36. Overall survival in patients with BRAF-mutant melanoma receiving encorafenib plus binimetinib versus vemurafenib or encorafenib (COLUMBUS): a multicentre, open-label, randomised, phase 3 trial.
Dummer R; Ascierto PA; Gogas HJ; Arance A; Mandala M; Liszkay G; Garbe C; Schadendorf D; Krajsova I; Gutzmer R; Chiarion Sileni V; Dutriaux C; de Groot JWB; Yamazaki N; Loquai C; Moutouh-de Parseval LA; Pickard MD; Sandor V; Robert C; Flaherty KT
Lancet Oncol; 2018 Oct; 19(10):1315-1327. PubMed ID: 30219628
[TBL] [Abstract][Full Text] [Related]
37. Risk factors for severe rash with use of vemurafenib alone or in combination with cobimetinib for advanced melanoma: pooled analysis of clinical trials.
Hopkins AM; Rathod AD; Rowland A; Kichenadasse G; Sorich MJ
BMC Cancer; 2020 Feb; 20(1):157. PubMed ID: 32103736
[TBL] [Abstract][Full Text] [Related]
38. Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF-mutant melanoma (COLUMBUS): a multicentre, open-label, randomised phase 3 trial.
Dummer R; Ascierto PA; Gogas HJ; Arance A; Mandala M; Liszkay G; Garbe C; Schadendorf D; Krajsova I; Gutzmer R; Chiarion-Sileni V; Dutriaux C; de Groot JWB; Yamazaki N; Loquai C; Moutouh-de Parseval LA; Pickard MD; Sandor V; Robert C; Flaherty KT
Lancet Oncol; 2018 May; 19(5):603-615. PubMed ID: 29573941
[TBL] [Abstract][Full Text] [Related]
39. Survival in adult patients with BRAFV600 mutation-positive advanced melanoma: a noninterventional ambispective study of patients with cobimetinib combined with vemurafenib during the French early access program: MELANIS study.
Meyer N; Pérol D; Duval-Modeste AB; El Adaoui L; Lelarge Y; Niarra R; Mateus C
Melanoma Res; 2022 Aug; 32(4):269-277. PubMed ID: 35635532
[TBL] [Abstract][Full Text] [Related]
40. Vemurafenib in combination with cobimetinib in relapsed and refractory extramedullary multiple myeloma harboring the BRAF V600E mutation.
Mey UJM; Renner C; von Moos R
Hematol Oncol; 2017 Dec; 35(4):890-893. PubMed ID: 27641727
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
